CYP46A1 and Huntington disease: Recently, a noninvasive CYP46A1-targeted PET tracer (18F-Cholestify) has emerged, offering precise quantification of CYP46A1 abundance and cholesterol metabolism across various brain regions in rodents, nonhuman primates, and humans, thereby providing valuable insights into cholesterol homeostasis in HD and other conditions [131].